Cumberland Pharmaceuticals Inc. Business Acquisition, Pro Forma Revenue
Cumberland Pharmaceuticals Inc. (CPIX) reported Business Acquisition, Pro Forma Revenue of $42.01 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-13.
Discontinued › Income Statement › Other Income
us-gaap:BusinessAcquisitionsProFormaRevenue · last filed 2023-03-13
- Cumberland Pharmaceuticals Inc. business acquisition, pro forma revenue for fiscal 2022 was $42.01M, a 16.12% decline from fiscal 2021.
- Cumberland Pharmaceuticals Inc. business acquisition, pro forma revenue for fiscal 2021 was $50.09M.
| Period end | Business Acquisition, Pro Forma Revenue 12 month |
|---|---|
| 2022-12-31 | $42.01M 10-K · filed 2023-03-13 |
| 2021-12-31 | $50.09M 10-K · filed 2023-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |